Therapy developer Alumis prices U.S. IPO at $16 per share
28/06/2024 05:12
June 27 (Reuters) - Alumis ALMS.O has priced its
initial public offering of 13.1 million shares at $16 apiece,
the therapy developer said late on Thursday.
(Reporting by Disha Mishra in Bengaluru; Editing by Mrigank
Dhaniwala)
((Disha.Mishra@thomsonreuters.com;))
Recent news on Alumis
See all newsBrief: Alumis Says Envudeucitinib Improves Psoriasis Symptoms in Phase 3 Data
U.S. RESEARCH ROUNDUP-Adobe, Dell Technologies, Zscaler
Alumis set for worst day after lupus drug misses main goal in mid-stage trial
Alumis eyes late-stage lupus study despite trial miss (updated)
Alumis tumbles after lupus drug misses main goal in mid-stage trial